Sign in

    Mark Fram • TD Cohen

    Mark Fram is an Equity Research Analyst at TD Cohen, specializing in financial sector analysis with an emphasis on banks and asset management firms. He covers prominent companies within this space and is recognized for thorough financial modeling and industry insight, though specific performance metrics and rankings have not been publicly disclosed. Fram began his analyst career in the early 2010s and has built experience exclusively at TD Cohen, advancing through progressively senior roles over his tenure. He holds FINRA Series 7 and 63 licenses, demonstrating compliance with U.S. securities regulatory requirements and a commitment to professional standards.

    Mark Fram's questions to Kyverna Therapeutics Inc (KYTX) leadership

    Mark Fram's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q3 2024

    Question

    Mark Fram asked about the reliability of TH2 biomarker data from the KT61 healthy volunteer study compared to historical data for Dupilumab, and questioned if savings from deprioritizing oncology would be reinvested.

    Answer

    Founder, President, and CEO Nellie Monofi emphasized that the primary goal is demonstrating STAT6 protein degradation, the most direct biomarker, and cautioned against over-analyzing variable downstream markers like IgE and TARC. CFO Bruce Jacobs confirmed that any savings from the oncology pipeline shift will be reinvested into the immunology programs, leaving the company's cash runway guidance unchanged.

    Ask Fintool Equity Research AI